Nature Biotechnology
23, 157 (2005)
doi:10.1038/nbt0205-157
Stock options could no longer be the carrotStacy Lawrence
San Francisco
A new ruling which forces US companies to account for stock options as expenses could penalize biotech companies. Until now, stock options have been an incentive to recruit top managers who would otherwise prefer larger companies.
|
